Compare Abbott Laboratories (ABT) vs Duke Energy Corp (DUK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Duke Energy Corp — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while Duke Energy Corp trades at $127.67 (market cap $99.96B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Duke Energy Corp pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| ABT | DUK | |
|---|---|---|
Market Cap | $166.94B | $99.96B |
Sector | Health | Utilities |
52-Week High | $136.62 | $133.46 |
52-Week Low | $82.57 | $113.99 |
Enterprise Value | $193.69B | $190.00B |
Dividend Yield | 2.63% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Duke Energy (DUK) trades at $128.22, down 1.06% on the day, with a bullish technical signal supported by moving averages. The company shows steady revenue growth, reaching $32.24B in 2025, and has beaten earnings estimates for the last three quarters. A $1.07 dividend is scheduled for June 2026. Analyst consensus is a Buy with a $137.67 price target, though the stock faces headwinds from high debt levels and regulatory pressures.
DUK presents a stable investment with consistent earnings and a solid dividend, but investors should weigh the upside from infrastructure investments against rising debt and regulatory risks. The stock's current valuation is reasonable, with potential for moderate growth if execution on its $103B capital plan remains on track.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →
